{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:54:33Z","timestamp":1792457673548,"version":"4.5.0"},"reference-count":25,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Hand (New York, N,Y.)"],"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for glycemic control, but their relationship with diabetes-related musculoskeletal conditions remains unclear. This study compared rates of carpal tunnel syndrome (CTS), carpal tunnel release (CTR), and CTR complications in patients with type 2 diabetes mellitus (T2DM) with and without GLP-1 RA use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Adult T2DM patients were identified using the TriNetX database. The primary analysis compared patients with versus without GLP-1 RA use. The secondary analysis examined T2DM patients with CTS, stratified by GLP-1 RA exposure. The tertiary analysis included T2DM patients with GLP-1 RA use within 6 months before CTR versus controls without preoperative exposure. Cohorts were propensity-matched for demographics and comorbidities. Outcomes included CTS incidence (primary analysis), CTR incidence (secondary analysis), and 90-day postoperative complications (tertiary analysis).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The primary analysis identified 555\u2009267 matched pairs. Carpal tunnel syndrome incidence was 4.8% in GLP-1 RA users versus 5.5% in nonusers (relative risk [RR] 0.886, 95% confidence interval [CI] 0.872, 0.901). Conversely, GLP-1 RA use was associated with higher CTR prevalence (RR 1.138, 95% CI 1.104, 1.174). Postoperative complication rates, including infection, wound dehiscence, complex regional pain syndrome (CRPS), and stiffness, were comparable between groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Glucagon-like peptide-1 receptor agonist use was associated with reduced CTS incidence but higher CTR prevalence, without differences in postoperative complication rates. These findings suggest GLP-1 RAs may exert protective effects on musculoskeletal pathology and do not necessitate cessation before CTR.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/15589447261422503","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T16:29:05Z","timestamp":1771604945000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Glucagon-Like Peptide-1 Receptor Agonist Use Is Associated With Decreased Incidence of Carpal Tunnel Syndrome in Patients With Type 2 Diabetes: A Propensity-Matched Analysis"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3878-5183","authenticated-orcid":false,"given":"Kyle","family":"Stump","sequence":"first","affiliation":[{"name":"Temple University, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianly","family":"Centeno","sequence":"additional","affiliation":[{"name":"Temple University, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alec","family":"Talsania","sequence":"additional","affiliation":[{"name":"Temple University Hospital, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Morar","sequence":"additional","affiliation":[{"name":"Temple University, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Wiekrykas","sequence":"additional","affiliation":[{"name":"Temple University Hospital, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/147323000803600315"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcv106"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.2337\/dci25-0012"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinme.2025.100498"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0034"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076410"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-023-05988-3"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-0829"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jse.2024.11.041"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0275598"},{"key":"e_1_3_2_13_2","unstructured":"Wipperman J Penny ML. Carpal tunnel syndrome: rapid evidence review. Am Fam Physician. 2024;110(1):52-57. https:\/\/www.aafp.org\/pubs\/afp\/issues\/2024\/0700\/carpal-tunnel-syndrome.html"},{"key":"e_1_3_2_14_2","unstructured":"TriNetX. The global health research network. Published 2024. Accessed September 10 2025. https:\/\/trinetx.com"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.05.037"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyad187"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.5956"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1042\/CS20060247"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rcsop.2021.100022"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2018.3509"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1148209"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2023.11.009"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-023-06072-6"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.16242"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.3.565"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15038"}],"container-title":["HAND"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15589447261422503","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15589447261422503","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15589447261422503","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:30:56Z","timestamp":1777447856000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15589447261422503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":25,"alternative-id":["10.1177\/15589447261422503"],"URL":"https:\/\/doi.org\/10.1177\/15589447261422503","relation":{},"ISSN":["1558-9447","1558-9455"],"issn-type":[{"value":"1558-9447","type":"print"},{"value":"1558-9455","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"article-number":"15589447261422503"}}